Who is sponsoring ADAPT?

ADAPT is sponsored by Walter Ling.

What condition does ADAPT study?

ADAPT studies Methamphetamine Use Disorder.

What drugs are being tested in ADAPT?

Interventions: naltrexone plus bupropion.

Last reviewed 2020-03-09 · How we verify

CTN-0054 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT) for Methamphetamine Use Disorder

NCT01982643 Phase 1/Phase 2 COMPLETED Results posted

The aim of this 2-stage, 3-site study is to investigate the effectiveness and safety of a combination of extended-release depot naltrexone plus extended-release bupropion as a potential pharmacotherapy for methamphetamine (MA) use disorder.

Details

Lead sponsor	Walter Ling
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	49
Start date	2013-11
Completion	2015-02

Conditions

Methamphetamine Use Disorder

Interventions

naltrexone plus bupropion

Primary outcomes

Participants Categorized as "Responders" — Weeks 4-8
Study "Responders" were defined as participants providing six MA-negative urine tests of eight administered in the evaluation period (the last four weeks of the active medication phase), including the last test collected in the final study week of the active medication phase.

Countries

United States